Pharma Focus Asia
KP - Choose our fully recyclable blister films

Eli Lilly Japan and Mitsubishi Tanabe Pharma Introduced Mounjaro® subcutaneous injection 2.5 mg / 5 mg ATEOS®

Eli Lilly Japan and Mitsubishi Tanabe Pharma Corporation has introduced “Mounjaro® subcutaneous injection 2.5 mg / 5 mg ATEOS®”.

The world's first long-acting GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, Mounjaro is a first-in-class medicine that activates both the GLP-1 and GIP receptors.

The structure of the Mounjaro is based on a single molecule natural GIP peptide sequence, modified to bind to the GLP-1 receptor, and selectively acts for a long time to improve blood glucose. Mounjaro is a new class of treatment options for many people living with type 2 diabetes who need it.

Mounjaro with a single-use auto-injector (ATEOS) is delivered once in a week as a subcutaneous injection. The needle is inserted automatically consisting of a special pen with a pre-installed needle pressing the injection button under the skin and a single dose of the filled drug is injected with this needle. This injection does not require the patient to set the dose or handle the needle.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024